The Filing Desk

AirSculpt Technologies

AIRS · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

AIRS · Last close · November 19, 2026
$0.65
Value AirSculpt Technologies yourself

AirSculpt Technologies' revenue fell 15.8% to $152 million in fiscal 2025. Its operating margin was −7.6%, down from −0.9% a year earlier. Free cash flow was $1 million. The diluted share count rose 4.8%.

AirSculpt Technologies, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 31, 2026 · 0001870940-26-000011 Updated
Revenue
$152M
15.8%
Operating margin
−7.6%
6.7 pts
Net income
−$12M
 
Free cash flow
$1M
 
Return on capital
−6.6%
5.8 pts
Market cap
$47M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What AirSculpt Technologies does

AirSculpt offers a body contouring procedure that removes fat and tightens skin without needles, scalpels, stitches or general anesthesia, according to the company. It also offers fat transfer procedures that use the patient's own fat, and treatments for skin laxity and cellulite. Procedures are done only at its own offices.

Patients pay for the procedures. The company performed 11,852 body contouring procedures in 2025. It markets mainly through its website, social media, celebrity and influencer endorsements and word-of-mouth referrals, and it shows before-and-after photos.

As of March 31, 2026 it ran 31 centers across 20 U.S. states and Canada. Its centers work with affiliated professional associations that employ the surgeons.

Its biggest risks, as it describes them

  • Harm to the AirSculpt brand through changing tastes or bad publicity.
  • Depending on a single procedure whose market acceptance may not grow.
  • Too few patients, or patients unhappy with results.
  • Limited supply of the surgeons and licensed staff it needs.
  • Relying on one third-party manufacturer for key parts of its tools.
From AirSculpt Technologies's annual report on Form 10-K, filed March 31, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

AirSculpt Technologies lost money in fiscal 2025: a net loss of $12 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments25101088
Debt incl. finance leases8384727056
Net debt (negative means net cash)5774616248
Net debt to EBITDA2.6x21.0x3.1x6.0x39.0x
Debt to equity1.0x1.2x0.9x0.9x0.6x
Interest coverage3.2x−0.7x1.5x−0.2x−1.9x
Current ratio1.8x0.8x0.8x0.6x0.6x
Quick ratio1.8x0.8x0.8x0.6x0.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project AirSculpt Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What AirSculpt Technologies says to expect

  • Full year 2026: revenueThe Company is reducing its full-year 2026 revenue and Adjusted EBITDA guidance as follows: • Revenue in the range of approximately $144 million to $146 million, compared to the previous range of $151 million to $157 million; and
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 6, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $2.0 million of AirSculpt Technologies shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Apr 17, 2026Jorey Chernett10% ownerBought40,000$2.54$101,600Form 4
Apr 14, 2026Jorey Chernett10% ownerBought20,000$2.60$52,000Form 4
Apr 7, 2026Jorey Chernett10% ownerBought60,000$2.93$175,800Form 4
Apr 3, 2026Jorey Chernett10% ownerBought90,000$2.82$253,800Form 4
Mar 23, 2026Jorey Chernett10% ownerBought50,000$2.91$145,500Form 4
Mar 20, 2026Jorey Chernett10% ownerBought40,000$2.77$110,800Form 4
Mar 19, 2026Jorey Chernett10% ownerBought77,702$2.64$205,133Form 4
Mar 17, 2026Jorey Chernett10% ownerBought83,000$2.56$212,480Form 4
Mar 16, 2026Jorey Chernett10% ownerBought105,848$2.43$257,211Form 4
Mar 11, 2026Jorey Chernett10% ownerBought88,000$2.15$189,200Form 4
Mar 6, 2026Jorey Chernett10% ownerBought45,600$2.00$91,200Form 4
Mar 4, 2026Jorey Chernett10% ownerBought30,000$1.87$56,100Form 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 83 of 83 of 8
Rule of 4023.2%−9.4%−15.4%
Altman Z''0.59−0.25−0.63
Accruals ratio−13.9%−9.3%−7.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassPass
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassPass
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailFail
F-score6 of 83 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put AirSculpt Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AirSculpt TechnologiesFY25−15.8%−7.6%0.5%−6.6%39.0x3
GrailFY2517.2%−382.0%−203.8%———Compare
SBC Medical GroupFY25−15.5%38.9%13.4%38.4%−1.7x4Compare
RidgetechFY2610.2%−1.4%−1.1%———Compare
bioteFY25−2.5%18.5%15.7%—2.0x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue4163133169196180152
Revenue growth—52.2%112.4%26.6%16.1%−8.0%−15.8%
Gross profit———————
Research and development———————
Operating income11016−410−2−12
Net income−2811−15−4−8−12
Diluted EPS (US$)——−0.01−0.26−0.08−0.14−0.19
Diluted shares (millions)——5656575860
Cash flow
Cash from operations514272424113
Capital expenditure4471310142
Free cash flow010201214−31
Dividends paid00023000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation007301842
Balance sheet at fiscal year end
Cash and short-term investments51025101088
Debt incl. finance leases—328384727056
Total assets—180201201204213187
Total liabilities—56117130120135100
Shareholders' equity——8471837888
Margins and ratios
Gross margin———————
Operating margin1.6%16.0%11.8%−2.7%5.0%−0.9%−7.6%
Net margin−5.4%12.1%7.9%−8.7%−2.2%−4.5%−7.7%
Free cash flow margin1.2%16.4%14.6%6.8%7.2%−1.5%0.5%
Rule of 40 (growth + FCF margin)—68.6%127.0%33.4%23.2%−9.4%−15.4%
Return on capital———−2.5%3.4%−0.9%−6.6%
Return on equity———−19.0%−5.5%−10.0%−14.1%
Return on assets——5.5%−7.3%−2.1%−3.9%−5.8%
Net debt to EBITDA—1.4x2.6x21.0x3.1x6.0x39.0x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: AirSculpt Technologies' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with AirSculpt Technologies.